Evoke Pharma Inc. (EVOK) Shares Up 10.4%
Shares of Evoke Pharma Inc. (NASDAQ:EVOK) shot up 10.4% during trading on Wednesday . The company traded as high as $2.78 and last traded at $2.77, with a volume of 1,345,277 shares changing hands. The stock had previously closed at $2.51.
A number of brokerages have recently commented on EVOK. Northland Securities cut shares of Evoke Pharma from an “outperform” rating to a “market perform” rating in a report on Monday, July 18th. Zacks Investment Research upgraded shares of Evoke Pharma from a “hold” rating to a “buy” rating and set a $5.50 target price on the stock in a report on Tuesday, May 3rd. Feltl & Co. cut shares of Evoke Pharma from a “strong-buy” rating to a “sell” rating in a report on Monday, July 18th. Brean Capital cut shares of Evoke Pharma from a “buy” rating to a “hold” rating in a report on Monday, July 18th. Finally, Rodman & Renshaw restated a “buy” rating and set a $27.00 target price on shares of Evoke Pharma in a report on Monday, July 11th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and three have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $13.34.
The company’s market capitalization is $18.53 million. The stock has a 50-day moving average of $5.49 and a 200-day moving average of $4.72.
Evoke Pharma (NASDAQ:EVOK) last released its earnings results on Wednesday, May 11th. The specialty pharmaceutical company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.41) by $0.04. On average, equities research analysts expect that Evoke Pharma Inc. will post ($1.43) earnings per share for the current year.
In other Evoke Pharma news, major shareholder Parters Vii L. P. Domain sold 344,120 shares of the stock in a transaction on Thursday, May 26th. The stock was sold at an average price of $4.70, for a total value of $1,617,364.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.
Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.